Dr. Paul Sorajja presents Tripair™ at TCT San Francisco

Leading interventional cardiologist Dr. Paul Sorajja presented Tripair™, Coramaze’s innovative transcatheter therapy for tricuspid repair, at the Cardiovascular Research Foundation’s TCT meeting in San Francisco last week. The company’s leadership team was in San Francisco to connect with physicians, innovators, and industry leaders, and to exchange insights on how Tripair™ could contribute to advancing care for patients worldwide.

During the innovation session, Dr. Sorajja explained that Tripair™ was designed to overcome the anatomical and operational complexities that leave behind 75% of current tricuspid regurgitation patients.

Tripair™ brings what the company terms an “enabling simplicity” to address existing complexities. First-in-human data shows it to be simple, safe, and efficient, with median deployment times of 30 minutes, a novel self-centering approach, and full retrievability.